Home LiteratureArticle Details

PMID: 87620 Published · ppublish English Clinical Trial Controlled Clinical Trial Journal Article

Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.

Lancet (London, England) ·Vol. 1 ·No. 8123 ·1979-05-05 ·Pages 954-6

Corsini GU, Del Zompo M, Gessa GL, Mangoni A

Abstract

Apomorphine in combination with a peripheral dopamine receptor blocker (domeperidone) was administered to four parkinsonian patients in a double-blind placebo-controlled study. The therapeutic efficacy of apomorphine was not reduced by domperidone, while nausea, drowsiness, sedation, and arterial hypotension were prevented. Combination of domperidone with dopamine agonists may result in more effective treatment of Parkinson's disease.

MeSH Terms

Apomorphine/administration & dosage Benzimidazoles/administration & dosage Blood-Brain Barrier/drug effects Clinical Trials as Topic Double-Blind Method Drug Evaluation Drug Therapy, Combination Female Humans Male Middle Aged Parkinson Disease/drug therapy Piperidines/administration & dosage Placebos Receptors, Dopamine/drug effects

Chemicals

Benzimidazoles Piperidines Placebos Receptors, Dopamine Apomorphine

Authors & Affiliations

4 authors, click to expand affiliations / ORCID

Corsini G U

Del Zompo M

Gessa G L

Mangoni A

Article Info

Journal

Lancet (London, England)

Abbr.

Lancet

ISSN

0140-6736

DOI

10.1016/s0140-6736(79)91725-2

Published

1979-05-05

Pages

954-6

Language

English

Region

England

NLM ID

2985213R

Subset

External Links

PubMed source DOI: 10.1016/s0140-6736(79)91725-2 View journal details

Analysis Services

Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.

Contact

WeChat Official Account